QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Celebrate Midsummer with Quantify i Vienna! ?
Are you attending #EASLCongress this week? Quantify’s Emilie Toresson Grip is on site and would be happy to connect!
Tomorrow, she will present the poster “Healthcare resource use and costs among patients with primary sclerosing cholangitis in Sweden – a retrospective population-based cohort study”( SAT-115), co-authored with Quantify’s Martina Aldvén and Oskar Ström, and on Saturday she will present the poster “Prevalence of NAFLD and advanced fibrosis in Stockholm, Sweden” (SAT-399-YI) […]
2023 Nordic Rare Disease Summit
Studying rare diseases in real-world evidence often comes with challenges, such as lack of disease-specific diagnosis codes and complex definition of relevant endpoints. Over the years, Quantify has faced these challenges on several occasions together with our clients – a demanding but also rewarding puzzle, as the need to generate evidence for the benefit of patients with rare diseases is high.
We […]
Denmark joins the FINOSE collaboration!
Denmark, through the Danish Medicines Council, will join FINOSE! We at Quantify foresee that this can potentially be a great preparation for both HTA bodies and pharmaceutical manufacturers for the upcoming EU HTA regulation. The addition of Denmark to FINOSE will likely also make the FINOSE pathway more attractive for pharmaceutical companies, when considering their HTA and market access options in the Nordics. Quantify, with our vast experience in […]
ISPOR Boston day 1
The Quantify team has had a fantastic first day at #isporannual! Today’s schedule was full with many meetings and interesting program sessions.
One thing is clear – Nordic RWD has great value for US and global stakeholders!
Looking forward to seeing you tomorrow at booth 1217